SLC5A5 and prostate carcinoma: After the successful test of the first construct containing the PSA promoter used to confer efficient functional NIS expression in prostate cancer xenografts[77], several other tumor-specific promoters have shown the capacity to drive NIS expression in specific tumor tissue and determine the radioiodide inhibition of tumor growth in animal experimental models.